Cover Image

Editorial: Checkpoint Inhibitor‐Induced Liver Injury—Time to Abandon CTCAE?

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Kelly Torosian, Shravan Dave
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Editorial: Steatotic Liver Diseases Emerge as Rapidly Growing Drivers of Primary Liver Cancer in the United States
by: Kelly Torosian, et al.
Published: (2025)

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance
by: Romeo Kuo‐Cheng Wu, et al.
Published: (2025)

Editorial: NAFLD, NAFLD, or MASLD: what's in a name?
by: Maryam Zafer, et al.
Published: (2024)

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance. Authors' Reply
by: Terry Cheuk‐Fung Yip, et al.
Published: (2025)

Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions
by: Mohammad Saeid Rezaee‐Zavareh, et al.
Published: (2026)

Editorial: Cephalosporin‐Induced Liver Injury—Interesting but Tricky
by: Einar S. Björnsson
Published: (2025)

Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions. Authors' reply
by: L. Aceituno, et al.
Published: (2026)

Editorial: Cephalosporin‐Induced Liver Injury—Interesting but Tricky. Authors' Reply
by: Raj Vuppalanchi, et al.
Published: (2025)

Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas
by: Yi‐Ping Hung, et al.
Published: (2024)

Review Article: Drug‐Induced Liver Injury Associated With Antibody‐Based Therapies in Haematologic Malignancies
by: Mengmeng Lin, et al.
Published: (2025)

Editorial: High Baseline ALT Level Confers Risk of Hepatic Adverse Events During Immune Checkpoint Inhibitors Treatment: A Call for Caution
by: Ze‐Hua Zhao, et al.
Published: (2025)

Editorial: Time to Genotype—Genetic Risk and Prognosis in Steatotic Liver Disease
by: Rosellina M. Mancina, et al.
Published: (2025)

Editorial: Liver and Non‐Liver Outcomes Between Different Subtypes of Steatotic Liver Disease
by: Jee‐Fu Huang, et al.
Published: (2026)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue?
by: Louise J. M. Alferink, et al.
Published: (2024)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue? Authors' Reply
by: Ting Wang, et al.
Published: (2024)

Editorial: The Role of Liver Biopsy in ANA Positive Subjects
by: Einar S. Björnsson
Published: (2026)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol
by: Karen Cheuk‐Ying Ho, et al.
Published: (2025)

Letter: Methodological Considerations in Comparing Liver Outcomes of Glucagon‐Like Peptide‐1 Receptor and Sodium Glucose Cotransporter‐2 Inhibitors
by: Cheng‐Hsien Hung, et al.
Published: (2025)

Editorial: The Impact of Socioeconomic and Ethnic Factors on Chronic Liver Disease
by: Wah Loong Chan, et al.
Published: (2024)

Editorial: Balancing the Yin and Yang of Alcohol‐Associated Liver Disease—Integrating Pathophysiology, Liver‐Directed Therapy and Addiction Management
by: Raj Vuppalanchi, et al.
Published: (2025)

Editorial: Proton Pump Inhibitors and the Changing Face of Spontaneous Bacterial Peritonitis
by: S. Quickert, et al.
Published: (2026)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
by: Federica Tavaglione, et al.
Published: (2025)

Editorial: The Role of Liver Biopsy in ANA Positive Subjects. Authors' Reply
by: David Mehdi Asgher Niazi, et al.
Published: (2026)

Editorial: Terlipressin Induced Bradycardia
by: Nancy Reau, et al.
Published: (2025)

Editorial: Silent But Detectable—High‐Throughput Proteomics to Identify Clinically Significant Liver Disease
by: Emily Stephenson, et al.
Published: (2026)

Letter: Comparison of the Efficacy of Adjuvant PD‐1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Related HCC Versus Other Aetiologies
by: Jia‐Yong Su, et al.
Published: (2025)

Editorial: Decoding ACLF—Sub‐Phenotyping to Advance Precision Medicine in Acute‐On‐Chronic Liver Failure
by: Amy Sangam, et al.
Published: (2024)

Editorial: Two Common Risks, One Greater Harm—Diabetes and Alcohol in Steatotic Liver Disease
by: Stine Johansen, et al.
Published: (2026)

Letter: Comparing the Efficacy of Adjuvant PD–1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease Related HCC Versus Other Aetiologies—Authors' Reply
by: Isabella Lurje, et al.
Published: (2025)

Editorial: Tumour Burden Score and Extrahepatic Progression After TACE —Refining Risk Stratification Beyond the Liver
by: Chien‐Wei Su
Published: (2026)

Editorial: JAK to JAK—Navigating Intra‐Class JAK Inhibitor Switching in Inflammatory Bowel Disease. Authors' Reply
by: Mathieu Uzzan, et al.
Published: (2025)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors
by: Stefan Mauss
Published: (2025)

Editorial: Redefining Safety in Post‐Liver Transplant IBD —Why Therapeutic Effectiveness Is the Ultimate Shield. Authors' Reply
by: Simone Chin, et al.
Published: (2025)

Editorial: Extracellular Matrix Biomarkers Illuminate the Architecture of Portal Hypertension in End‐Stage Liver Disease—Authors' Reply
by: Mattias Mandorfer, et al.
Published: (2025)

Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
by: Pojsakorn Danpanichkul, et al.
Published: (2025)

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
by: Jessica D. Lee, et al.
Published: (2025)

Diagnostic Impact of Liver Biopsy Among Antinuclear Antibody Positive Individuals With Mild Liver Enzyme Elevation
by: David Mehdi Asgher Niazi, et al.
Published: (2026)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply
by: Ying‐Nan Tsai, et al.
Published: (2025)

Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply
by: Maral Amangurbanova, et al.
Published: (2024)

Editorial: Prevalence of Suspected Metabolic Dysfunction‐Associated Steatotic Liver Disease in Adolescents in the United States Using Updated Diagnostic Criteria
by: Julie Bonn, et al.
Published: (2025)